These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2054167)

  • 1. Properties of a deep Proteus R mutant isolated from clinical material.
    Krajewska-Pietrasik D; Rózalski A; Bartodziejska B; Radziejewska-Lebrecht J; Mayer H; Kotełko K
    APMIS; 1991 Jun; 99(6):499-506. PubMed ID: 2054167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannose-resistant Proteus-like and P. mirabilis fimbriae have specific and additive roles in P. mirabilis urinary tract infections.
    Zunino P; Sosa V; Schlapp G; Allen AG; Preston A; Maskell DJ
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):125-33. PubMed ID: 17854474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-8 response in cells from the human urinary tract induced by lipopolysaccharides of Proteus mirabilis O3 and O18.
    Chromek M; Stankowska D; Dadfar E; Kaca W; Rabbani H; Brauner A
    J Urol; 2005 Apr; 173(4):1381-4. PubMed ID: 15758809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of spontaneously agglutinating Proteus mirabilis strains from bacteriuric patients.
    Krajewska-Pietrasik D; Larsson P; Zych K; Wlodarczyk J; Gromska W
    APMIS; 1991 Oct; 99(10):956-60. PubMed ID: 1930968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies of epitope specificity of polyclonal antibodies against Proteus mirabilis R mutants].
    Bartodziejska B; Radziejewska-Lebrecht J; Lipińska M; Ziółkowski A; Rózalski A
    Med Dosw Mikrobiol; 1993; 45(1):99-102. PubMed ID: 7694017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human complement activation by smooth and rough Proteus mirabilis lipopolysaccharides.
    Kaca W; Arabski M; Fudała R; Holmström E; Sjöholm A; Weintraub A; Futoma-Kołoch B; Bugla-Płoskońska G; Doroszkiewicz W
    Arch Immunol Ther Exp (Warsz); 2009; 57(5):383-91. PubMed ID: 19707721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fimbriae of uropathogenic Proteus mirabilis.
    Rocha SP; Pelayo JS; Elias WP
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):1-7. PubMed ID: 17640292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core region in Proteus mirabilis lipopolysaccharide.
    Kotełko K; Gromska W; Papierz M; Sidorczyk Z; Krajewska D; Szer K
    J Hyg Epidemiol Microbiol Immunol; 1977; 21(3):271-84. PubMed ID: 342599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model.
    Fraga M; Scavone P; Zunino P
    Antonie Van Leeuwenhoek; 2005 Jul; 88(1):25-34. PubMed ID: 15928974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and serological properties of the O-antigen of two clinical Proteus mirabilis strains classified into a new Proteus O77 serogroup.
    Drzewiecka D; Arbatsky NP; Shashkov AS; Staczek P; Knirel YA; Sidorczyk Z
    FEMS Immunol Med Microbiol; 2008 Nov; 54(2):185-94. PubMed ID: 18665848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmid-mediated multiple antibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection.
    Khan AU; Musharraf A
    Med Sci Monit; 2004 Nov; 10(11):CR598-602. PubMed ID: 15507850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tests for studying invasive properties of selected Proteus mirabilis strains].
    Bartodziejska B; Wykrota M; Rózalski A; Kaca W
    Med Dosw Mikrobiol; 2001; 53(3):277-82. PubMed ID: 11785185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flagellate and non-flagellate Proteus mirabilis in the development of experimental urinary tract infection.
    Zunino P; Piccini C; Legnani-Fajardo C
    Microb Pathog; 1994 May; 16(5):379-85. PubMed ID: 7815921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Examination of selected biological properties for swarm cells in Proteus mirabilis].
    Krajewska-Pietrasik D; Rózalski A; Zych K; Gromska W; Chomiczewski K; Kotełko K
    Med Dosw Mikrobiol; 1998; 50(1-2):21-9. PubMed ID: 9857610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotyping of clinical isolates belonging to Proteus mirabilis serogroup O36 and structural elucidation of the O36-antigen polysaccharide.
    Arabski M; Grabowski S; Konieczna I; Kaca W; Kondakova AN; Perepelov AV; Senchenkova SN; Shashkov AS; Knirel YA
    FEMS Immunol Med Microbiol; 2008 Aug; 53(3):395-403. PubMed ID: 18625011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pathogenic Potential of Proteus mirabilis Is Enhanced by Other Uropathogens during Polymicrobial Urinary Tract Infection.
    Armbruster CE; Smith SN; Johnson AO; DeOrnellas V; Eaton KA; Yep A; Mody L; Wu W; Mobley HLT
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregative adherence of uropathogenic Proteus mirabilis to cultured epithelial cells.
    Rocha SP; Elias WP; Cianciarullo AM; Menezes MA; Nara JM; Piazza RM; Silva MR; Moreira CG; Pelayo JS
    FEMS Immunol Med Microbiol; 2007 Nov; 51(2):319-26. PubMed ID: 17714491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation by Proteus mirabilis negatively charged lipopolysaccharides.
    Kaca W; Literacka E; Sjöholm AG; Weintraub A
    J Endotoxin Res; 2000; 6(3):223-34. PubMed ID: 11052177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and immunochemical studies on the lipopolysaccharide of the 'T-antigen'-containing mutant Proteus mirabilis R14/1959.
    Bartodziejska B; Radziejewska-Lebrecht J; Lipinska M; Knirel YA; Kononov LO; Chernyak AY; Mayer H; Rozalski A
    FEMS Immunol Med Microbiol; 1996 Feb; 13(2):113-21. PubMed ID: 8731019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel autotransporter of uropathogenic Proteus mirabilis is both a cytotoxin and an agglutinin.
    Alamuri P; Mobley HL
    Mol Microbiol; 2008 May; 68(4):997-1017. PubMed ID: 18430084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.